News
August 3, 2026: Peptide vendor sentenced to six years for “incredible trail of harm”
The man was sentenced to six years for deceptively marketing “research use only” chemicals, which the judge said left “an incredible trail of harm.”
[...]PSM joins PSI, Rx360 and PDSA in letter urging FDA to protect the traceable drug supply
PSM joined three other organizations for a sign-on letter explaining our concerns that unrestricted mass compounding increases the untraceable drug supply. An explosion of 503B compounding of these three substances, semaglutide, tirzepatide, and liraglutide, would dramatically increase the compounded medicine supply which is not serialized, and therefore, not traceable.
[...]July 27, 2026: FDA peptide panel narrowly votes to add unapproved drugs to compounding list
FDA’s Pharmaceutical Compounding Advisory Committee voted to add six of seven peptides to the 503A Bulk Drug Substance List, despite FDA scientists recommending against all of them because of limited evidence of their safety and effectiveness.
[...]PSM submits comment supporting the continued exclusion of GLP-1s from the 503B Bulks List
PSM supports the FDA’s proposal, which will help protect patient safety and the integrity of the drug approval process.
[...]Statement from Partnership for Safe Medicines Executive Director Shabbir Imber Safdar on the FDA PCAC vote to advance peptide compounding
The advisory committee voted to advance substances that FDA’s own scientists flagged as lacking adequate evidence of safety, efficacy, or quality. Its recommendation will inevitably be interpreted as an endorsement of broader clinical use. It is not.
[...]Death of woman in New York from compounded drug shows the risk of allowing compounding of untested substances
Fatality reported as the FDA’s Pharmacy Compounding Advisory Committee weighs adding more untested peptides to the compounding list
[...]July 20, 2026: North Carolina woman shares experience with hospitalization after telehealth prescribed weight loss drugs
She was given a dramatic increase in her prescribed dose, a change she questioned, but was told to follow the doctor’s instructions. Despite injecting a smaller amount than directed, she began violently vomiting within hours.
[...]Live event on safety on compounded GLP-1s
Join us in person in Washington DC on Wednesday July 26, 2026 for Axios Live “Examining Risk and Regulation in the GLP-1 Landscape” Speakers include The Honorable Nikki Budzinski (IL-13), Scott Kahan, M.D., M.P.H., F.T.O.S., Shabbir Imber Safdar, CFE, The Honorable Rudy Yakym (IN-02)
[...]July 13, 2026: Researchers find telehealth platforms prioritize “quick prescriptions over comprehensive care”
The study found that 91.8% of the platforms issued a prescription. In their questionnaire, which was used on every platorm, 98% asked about medical conditions, 93.9% asked about medications and allergies, and only 55.1% asked about eating disorder history.
[...]The five risks of taking unapproved peptides
The FDA is reconsidering adding a dozen peptides—seven in July; another four next February—to its Section 503A bulk drug substances list after excluding them over safety concerns in 2023. The review is happening at a time when Americans are turning to peptides at an unprecedented rate, driven by grifters in the online wellness space, who push these products for a profit without any clinical evidence they are either safe or effective.
[...]